Baidu
map

JCC:Vedolizumab 在治疗IBD中药物浓度与药物疗效的关系

2017-07-30 xuyihan MedSci原创

之前已经有报道表明Vedolizumab的血清浓度与IBD患者的临床缓解率成正相关关系。近期有一份研究进一步报道了Vedolizumab在IBD治疗中诱导缓解的作用。

研究人员收集了采用Vedolizumab治疗的患者第6周的血清浓度作为观察变量,将之与患者临床症状相关联。使用Logistics回归模型预测患者6周的vedolizumab累积血清浓度,探讨了患者第6周Vedolizumab浓度与药物疗效之间的潜在线性关系。

结果显示:更高的Vedolizumab浓度与较高的临床缓解率相关,在UC患者中这样的线性关系更加明显,总体来说,如果患者自身的白蛋白水平较高,粪钙卫蛋白水平较低,同时之前没有使用过其他生物制剂的话,Vedolizumab的使用能够带来较高的临床缓解率。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2007176, encodeId=418a200e17613, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sun Oct 08 01:52:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911871, encodeId=7f6719118e15e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 06 13:52:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263444, encodeId=128f1263444a0, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455221, encodeId=16db14552213f, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544457, encodeId=f2c0154445e38, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2007176, encodeId=418a200e17613, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sun Oct 08 01:52:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911871, encodeId=7f6719118e15e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 06 13:52:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263444, encodeId=128f1263444a0, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455221, encodeId=16db14552213f, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544457, encodeId=f2c0154445e38, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=)]
    2018-04-06 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=2007176, encodeId=418a200e17613, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sun Oct 08 01:52:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911871, encodeId=7f6719118e15e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 06 13:52:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263444, encodeId=128f1263444a0, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455221, encodeId=16db14552213f, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544457, encodeId=f2c0154445e38, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=)]
    2017-08-01 bnurmamat
  4. [GetPortalCommentsPageByObjectIdResponse(id=2007176, encodeId=418a200e17613, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sun Oct 08 01:52:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911871, encodeId=7f6719118e15e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 06 13:52:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263444, encodeId=128f1263444a0, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455221, encodeId=16db14552213f, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544457, encodeId=f2c0154445e38, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2007176, encodeId=418a200e17613, content=<a href='/topic/show?id=be3a8e81516' target=_blank style='color:#2F92EE;'>#药物疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87815, encryptionId=be3a8e81516, topicName=药物疗效)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLGtr9t89oicQdQSIeKmOQic1weIWfibJ7H24XnT8ic9wiaUMTnXByenuwicOj8Jib42ibHXNptnuiaKthhiaVw/132, createdBy=ac342500190, createdName=ms7524819409032184, createdTime=Sun Oct 08 01:52:00 CST 2017, time=2017-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911871, encodeId=7f6719118e15e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Fri Apr 06 13:52:00 CST 2018, time=2018-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263444, encodeId=128f1263444a0, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455221, encodeId=16db14552213f, content=<a href='/topic/show?id=4c0118331e3' target=_blank style='color:#2F92EE;'>#vedolizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18331, encryptionId=4c0118331e3, topicName=vedolizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78f5645466, createdName=yankaienglish, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1544457, encodeId=f2c0154445e38, content=<a href='/topic/show?id=ac3d6549e75' target=_blank style='color:#2F92EE;'>#浓度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65497, encryptionId=ac3d6549e75, topicName=浓度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16b213663040, createdName=12498974m55暂无昵称, createdTime=Tue Aug 01 13:52:00 CST 2017, time=2017-08-01, status=1, ipAttribution=)]

相关资讯

Measurement of disease activity in ulcerative colitis: Interobserver agreement a

Thia, K. T., E. V. Loftus, Jr., et al. (2011). "Measurement of disease activity in ulcerative colitis: Interobserver agreement and predictors of severity." Inflamm Bowel Dis 17(6): 1257-1264. BACKGRO

Inflamm bowel dis:溃疡性结肠炎患者早期结肠全切除风险的临床预测分析

溃疡性结肠炎患者中有一部分人群在确诊后数年后会进行结肠切除术,而哪些临床因素可以用来预测UC急性发作期住院的早期结肠癌切除的可能性呢?最近一项加拿大的基于人群的对照研究揭示了其中的秘密。

Inflamm bowel dis:miR-4728-3p通过调节信号通路抑制溃疡性结肠炎相关结肠直肠肿瘤

溃疡性结肠炎(UC)患者的肿瘤形成机制尚不清楚,最近有一项研究试图确定这一高危人群癌变发生的途径到底是怎么样的。

INFLAMM BOWEL DIS:粘膜抗菌反应谱和粪便微生物成分与初次诊断为溃疡性结肠炎患者的病程关系

溃疡性结肠炎(UC)的疾病进程在不同个体之间存在很大差异,目前尚不能准确预测。之前已经有研究证实,肠道微生物群落与宿主的免疫应答是维持肠道稳态的关键因素,可能与疾病的最终结局相关。最近,瑞典的研究人员筛选了一群初次诊断为溃结且未经过治疗的患者,并对他们的肠道黏膜抗菌反应谱和粪便微生物组成进行研究,以期能得到与疾病发展进程相关的研究结果。参与实验的患者都是第一次被诊断为溃疡性结肠炎且未经过治疗的,疾

Baidu
map
Baidu
map
Baidu
map